Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

June 13, 2017
Editas Medicine to Participate in Investor Conferences in June

May 31, 2017
Editas Medicine Names Andrew Hirsch to Board of Directors

May 15, 2017
Editas Medicine Announces First Quarter 2017 Results and Update

Read More News

Associated Team Members

Alexis Borisy